In fact, dual use of antibodies against CTLA-4 and PD-1 or PD-L1 has been associated with an increased risk of developing T1D (hazard ratio [HR] = 1.62), compared to the use of anti-PD-L1 or anti-PD-1 alone [38]. The gene discussed is CD274; the disease is type 1 diabetes mellitus.